VC believers back a $41M game plan for Enterprise Therapeutics' new group of respiratory drugs
Alex Mayweg wasn’t attracted to the team at Enterprise Therapeutics because they had some new, cutting-edge technology that would set the biotech world on fire. The Versant partner, and former top global chemist at Roche, had no eureka moment.
Instead, he was just deeply impressed by a group of experienced veterans with a handle on ion channel R&D work which could play a key role in controlling the mucus buildup that bedevils a large group of patients for a range of respiratory diseases like cystic fibrosis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.